Clinical benefit of treatment with eribulin mesylate for metastatic triple‐negative breast cancer: Long‐term outcomes of patients treated in the US community oncology setting

Clinical benefit of treatment with eribulin mesylate for metastatic triple‐negative breast cancer: Long‐term outcomes of patients treated in the US community oncology setting

Abstract Introduction Real‐world data are critical to demonstrate the consistency of evidence and external generalizability of randomized controlled trials (RCTs). This study examined characteristics and outcomes of metastatic triple‐negative breast cancer (mTNBC) patients treated with eribulin mesy...

Full description

Bibliographic Details
Main Authors: Sarah S. Mougalian, Ronda Copher, Jonathan K. Kish, Lindsay McAllister, Zhixiao Wang, Mary Broscious, David Garofalo, Janna Radtchenko, Bruce A. Feinberg
Format: Article
Language:English
Published: Wiley 2018-09-01
Series:Cancer Medicine
Subjects:
eribulin
metastatic breast cancer
real‐world
survival
triple negative
Online Access:https://doi.org/10.1002/cam4.1705

Internet

https://doi.org/10.1002/cam4.1705

Similar Items